Published

A suite of engineered mice for interrogating psychedelic drug actions.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Nature neuroscience
Date: 2026-08-06
Source: Europe PMC
DOI: 10.1038/s41593-026-02375-0
PubMed: 42563032

Derived topics and classifications

psilocybin Depression Anxiety PTSD Headache / Migraine Mechanism of Action Receptor Pharmacology Animal Study Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

A suite of engineered mice for interrogating psychedelic drug actions.2026-08-06

Related papers

Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15 Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01 Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophreniaNeuropsychopharmacology · 2026-07-18 Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric DisordersPsychiatry and Clinical Psychopharmacology · 2026-03-30 CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorderNeuropsychopharmacology · 2026-07-07 Psilocybin as a novel treatment for chronic pain.British journal of pharmacology · 2026-07-01 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.ACS pharmacology & translational science · 2026-03-13